SecBot SecBot
424B5 ·Filed May 18, 2026

GILD

GILEAD SCIENCES, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001104659-26-063199
Notable filing: 424B5
Actionable Insight • Neutral

Monitor Gilead's M&A pipeline, the $2.99B in net proceeds plus $4.7B term loan capacity signals potential for near-term acquisitions. The strong Q1 results and raised guidance provide fundamental support, but increased leverage warrants watching credit rating actions. No immediate catalyst for common equity from this debt offering alone.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$130.43
T+0 close · May 18, 2026 · via day close
Latest settled
+5.91%
T+60 · $138.14
Vs SPY
−0.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 19 $130.43entry
  2. T+1 · 6mo ago +0.14%α −0.90% · $130.61
  3. T+5 · 6mo ago +2.44%α +0.15% · $133.62
  4. T+20 · 5mo ago −2.45%α −4.71% · $127.23
  5. T+60 · 3mo ago +5.91%α −0.11% · $138.14

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Gilead Sciences is issuing $3.0 billion in senior unsecured notes across four tranches (2028-2034), with net proceeds of approximately $2.99 billion for general corporate purposes including acquisitions and strategic transactions. The offering follows strong Q1 2026 results (product sales ex-Veklury up 8% YoY, raised full-year guidance) and comes alongside a $4.7 billion term loan facility, of which $1.1 billion was drawn pre-closing. For common equity holders, this is a neutral capital structure event, debt issuance increases leverage modestly but funds growth initiatives without equity dilution.

Key Facts

  • $3.0 billion aggregate principal amount of senior notes across four tranches: $500M 4.250% due 2028, $1.0B 4.400% due 2029, $1.0B 4.600% due 2031, $500M 4.900% due 2034
  • Net proceeds estimated at ~$2.99 billion after underwriting discounts and expenses
  • Proceeds to be used for general corporate purposes including acquisitions, investments, and strategic transactions
  • Pro forma cash and marketable securities increase from $8.6B to $12.7B; total debt rises from $22.2B to $26.3B
  • Q1 2026 product sales ex-Veklury increased 8% YoY to $6.8B; total revenue up 4% to $7.0B
  • Non-GAAP diluted EPS of $2.03 vs $1.81 YoY; full-year product sales guidance raised to $30.0-30.4B from $29.6-30.0B
  • Notes are senior unsecured, unrated in filing, and not listed on any exchange
  • Offering follows strong Q1 earnings (filed May 7, 2026) and a $4.7B term loan facility entered in April 2026

Financial Impact

Debt issuance of $3.0B increases total debt by ~13.5% from $22.2B to $26.3B; pro forma cash increases by ~47% to $12.7B; net leverage remains manageable given $2.5B quarterly operating cash flow

debtcashinterest expenseleverage

Risk Factors

  • Increased leverage from $22.2B to $26.3B could pressure credit ratings if not deployed accretively
  • Proceeds earmarked for acquisitions carry execution risk and potential value destruction
  • Fixed-rate notes expose Gilead to above-market interest costs if rates decline
  • Structural subordination to subsidiary debt (~$3.7B in subsidiary obligations)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-063199
Document: tm2531124d2_ex-filingfees.htm0001104659-26-063199
Document: 0001104659-26-063199-index-headers.html0001104659-26-063199
Document: 0001104659-26-063199-index.html0001104659-26-063199
Document: 0001104659-26-063199.txt0001104659-26-063199

Track record

30 reports on GILD

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
  2. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
  3. Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $168.08 Now $167.58 −0.30% settles Feb 11
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
  6. Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
  7. Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
  8. Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
  9. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
  10. Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
Showing 10 of 30

US Market Status

Market Closed · Opens Wed (11h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 18, 2026